Type
. How can adherence with multi-drug therapy in leprosy be improved?. Leprosy review [Internet]. 2005;76(2):160-1. Available from: https://leprosyreview.org/article/76/2/16-0161
Type
. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Leprosy review [Internet]. 2005;76(2):127-43. Available from: https://leprosyreview.org/article/76/2/12-7143
Type
. Curing the stigma of leprosy. Leprosy review [Internet]. 2005;76(2):119-26. Available from: https://leprosyreview.org/article/76/2/11-9126
Type
. Reflections on the ILA African Leprosy Congress. Leprosy review [Internet]. 2005;76(2):108-11. Available from: https://leprosyreview.org/article/76/2/10-8111
Type
. Is there an answer? Is there a genetic basis for human susceptibility to leprosy?. IUBMB life. 2005;57(2):119-21.
Type
. [How leprosy has invaded the world]. Revue medicale suisse. 2005;1(22):1529.
Type
. [What is your diagnosis? Annular hypopigmented skin lesions in a 6-year-old child]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2005;12(7):1145-7.
Type
. Protective role of vitamin E on the oxidative stress in Hansen's disease (Leprosy) patients. European journal of clinical nutrition. 2005;59(10):1121-8.
Type
. Ulnar nerve abscess and relapse in a patient with indeterminate leprosy 1 year after completion of multidrug therapy. Pediatric neurosurgery. 2005;41(3):162-4.
Type
. Lucio's phenomenon: a case report and review of the literature. International journal of dermatology. 2005;44(7):566-71.